Pharmaceuticals, R&D Johnson & Johnson Neil Davie, Ph.D. Head, Late Development Cardiovascular, Metabolism & Pulmonary Hypertension Ruxandra Draghia-Akli, M.D., Ph.D. Global Head Johnson & Johnson Global Public Health R&D Janssen Research & Development ...
KG (King Pharmaceuticals) Happy New Year to all, Pete Earle Paolo Pezzutti enters: If I may humbly add my 2 cents: - bearish on S&P: 900 in dec - crisis in Europe will bring EURUSD down to 1.15 - gold will remain a safe have haven: up to 1500 - big winner: natural gas to ...
Find the Janssen portfolio of long-acting injections (LAIs) for schizophrenia treatment in adults. See full Prescribing & Safety Info, including Boxed WARNING.
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of erdafitinib. The reader is cautioned not to rely on these...
Call your doctor for medical advice about side effects.You may report side effects to the FDA at 1-800-FDA-1088.You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). Please read fullPrescribing Information, including Boxed Warnings, andMedicat...
actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals Inc., and/orJohnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including...
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Compounds of formula (I...
/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a...
WO1999023073A1 1999-05-14 BIPHENYL DERIVATIVES AS PHARMACEUTICALS WO2002018333A1 2002-03-07 PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS WO2004113297A2 2004-12-29 AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS WO2005047246A1 2005-05-26 ...
Combinations of levodopa and carbidopa can be found in currently marketed pharmaceuticals. Methods of making levodopa and carbidopa are known in the art. Other stated agents (active and inactive) are available from commercial sources. Dissolution of a composition of this invention in liquid can occur...